Loading...
•
Mar 31, 2021
Esperion Q1 2021 Earnings Report
Esperion's financial performance in Q1 2021 reflected revenue growth driven by increased product sales, offset by higher operating expenses and a net loss.
Key Takeaways
Esperion reported total revenue of $8.0 million for the first quarter of 2021, compared to $1.8 million for the first quarter of 2020. U.S. product revenue was $6.4 million, an increase from $0.9 million in the prior year. The company experienced a net loss of $90.9 million, or $3.50 per share, compared to a net loss of $78.2 million, or $2.84 per share, for the same period in 2020.
Total revenue increased to $8.0 million, driven by NEXLETOL and NEXLIZET sales.
U.S. product revenue reached $6.4 million, reflecting growing demand.
The company secured a major Medicare Part D contract covering approximately 8.5 million lives.
The balance sheet was strengthened with $80 million from expanded Daiichi Sankyo agreement and exercise of Oberland Capital funding.
Revenue by Segment
Forward Guidance
Esperion expects full-year 2021 operating expenses to be approximately $320 million to $340 million, inclusive of $30 million of non-cash, stock-based compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...